ArticleAmerican journal of translational research2026
Efficacy and safety of pyrotinib combined with trastuzumab and chemotherapy in patients with HER2-positive locally advanced breast cancer: a multicenter real-world study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis multicenter real-world investigation aimed to assess the outcomes resulting from the incorporation of pyrotinib into trastuzumab and chemotherapy regimens for the neoadjuvant treatment of individuals diagnosed with HER2-positive locally advanced breast cancer (LABC).
methodsA multicenter retrospective cohort analysis was carried out, including patients diagnosed with HER2-positive locally advanced breast cancer from nine medical institutions in Hebei Province, China. Participants were enrolled from January 2023 to June 2023 and followed until December 2025. Based on the neoadjuvant therapy received, patients were divided into two groups: trastuzumab plus chemotherapy (n=127) and pyrotinib plus trastuzumab and chemotherapy (n=101). The main assessment criterion focused on the rate of total pathological complete response (tpCR). Among the secondary evaluation metrics were the breast pathological complete response (bpCR) rate, the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), as well as adverse events related to the treatment.
resultsA total of 228 patients were analyzed. The pyrotinib group showed significantly higher tpCR rate (46.53% vs. 31.50%,
conclusionsIn a real-world setting the addition of pyrotinib to trastuzumab and chemotherapy significantly improved pathological and radiographic responses and prolonged PFS, albeit with an increased but manageable toxicity profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.